[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Osteoporosis and fragile fractures are common and preventable complication in rheumatoid arthritis (RA) . We recently reported that the frequency of osteoporosis among RA patients was 53.3%, that of vertebral fractures was 19.3%. They were much higher rates than those of general population. Earlier drug intervention is necessary to prevent these complications. RA patients with glucocorticoid (GC) should be treated according to "Guidelines on the management and treatment of glucocorticoid-induced osteoporosis" published by JBMSR in 2004. The bone of RA patients are likely to be in high-turnover state. Consequently bisphosphonates, especially alendronate and risedronate, are recommended to regulate bone metabolism, to increase bone mineral density and prevent incidental fractures in RA patients.
Nakayama
Hisanori
H
National Hospital Orgamnization, Sagamihara Hospital, Department of Rheumatology.
D019386:Alendronate / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate